Journal
CLINICAL MEDICINE INSIGHTS-CARDIOLOGY
Volume 9, Issue -, Pages 113-117Publisher
SAGE PUBLICATIONS LTD
DOI: 10.4137/CMC.S26624
Keywords
dyslipidemia; review; hyperlipidemia; cholesterol; HDL; HDL-C; LDL; monoclonal antibody; PCSK; PCSK9; proprotein; convertase; sublisin; kexin; statin; heart attack; myocardial infarction; low HDL; high density lipoprotein; HDL subclass; Biosynthesis; storage; elimination; paraoxonase-1; PON1; platelet activating factor; acetylhydrolase; PAF-AH; apolipoprotein; Apo; ApoA-I; ApoA-II; CETP; niacin; TRIUMPH; AIM-HIGH; HP2-THRIVE; endothelial lipase gene; LIPG; atheroprotective; alirocumab; praluent; evolocumab; repatha; ODYSSEY; OSLER
Categories
Ask authors/readers for more resources
Low HDL is an independent risk factor for myocardial infarction. This paper reviews our current understanding of HDL, HDL structure and function, HDL subclasses, the relationship of low HDL with myocardial infarction, HDL targeted therapy, and clinical trials and studies. Furthermore potential new agents, such as alirocumab (praluent) and evolocumab (repatha) are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
